| Attribute | Value | [@rpla]
|----------|-------|
| Symbol | RPL10A |
| Name | Ribosomal Protein L10A |
| Chromosome | 6p21.3 |
| NCBI Gene ID | 6146 |
| UniProt ID | P62906 |
| Protein Family | Ribosomal protein L10 family |
| Molecular Weight | ~24 kDa |
| Expression | Ubiquitous, high in brain and liver |
The RPL10A gene spans approximately 8.5 kb on chromosome 6p21.3 and consists of 7 exons. The gene encodes a protein of 216 amino acids that is highly conserved across eukaryotes, from yeast to humans [@rpla]. RPL10A belongs to the ribosomal protein L10P family, which is essential for ribosomal assembly and function. The protein is also known as p17, ribosomal protein P1, or nucleolin-like protein, reflecting its multiple cellular roles beyond ribosome biogenesis [@kraft2022].
Phylogenetic analysis reveals that RPL10A is one of the most conserved ribosomal proteins, suggesting critical functional importance. The gene has undergone minimal duplication events compared to other ribosomal proteins, indicating strong selective pressure to maintain a single functional copy [@lee2020].
RPL10A is a component of the large (60S) ribosomal subunit, where it plays a central role in ribosome assembly and function. The protein contains several functional domains:
The protein contains a conserved RPL10 signature motif that is essential for its function in translation. Structural studies have shown that RPL10A interacts directly with the ribosomal RNA and with other ribosomal proteins including RPL5 and RPL11, forming a critical bridge in the 60S subunit [@benshem2011][@gamalinda2014].
RPL10A undergoes several post-translational modifications that regulate its function:
RPL10A plays multiple roles in translation regulation beyond its structural function in the ribosome:
Ribosome biogenesis: RPL10A is essential for proper 60S subunit assembly in the nucleolus. Knockdown of RPL10A leads to defective ribosome assembly and reduced translation capacity [@chen2021].
Translation initiation: The protein interacts with eukaryotic initiation factors (eIFs) and participates in the formation of the 80S initiation complex.
Translation elongation: RPL10A contributes to the stabilization of the ribosomal complex during elongation.
Co-translational quality control: RPL10A interfaces with the ribosome-associated quality control (RQC) complex to handle stalled translation complexes.
Beyond translation, RPL10A has several extra-ribosomal functions:
RPL10A is ubiquitously expressed with highest levels in tissues with high protein synthesis demands:
Within the brain, RPL10A is expressed in neurons and glia, with particular enrichment in synaptic regions where local protein synthesis is crucial for synaptic plasticity [@holt2019].
Ribosomal dysfunction is a well-established hallmark of Alzheimer's disease, and RPL10A plays a key role in this process:
Translational impairment: Multiple studies have documented reduced translation efficiency in AD brain tissue. Ribosomes from AD hippocampus show decreased binding to mRNA and reduced activity [@wang2020]. RPL10A expression is altered in AD, contributing to the general translational deficit.
Amyloid-beta effects: Amyloid-beta oligomers directly impair translation by affecting ribosomal function. Studies show that Aβ accumulation leads to differential expression of ribosomal proteins including RPL10A [@hernandez2019].
Tau pathology: Hyperphosphorylated tau affects ribosomal function through multiple mechanisms. Tau interacts with ribosomal proteins and translation machinery, and RPL10A dysfunction may contribute to the characteristic translational deficits in AD [@b2021].
Synaptic translation: Local translation at synapses is crucial for memory formation and synaptic plasticity. In AD, synaptic translation is severely impaired, with RPL10A playing a role in this deficit. The protein's localization to dendritic spines suggests a role in activity-dependent translation [@rugerio2022].
RPL10A dysfunction contributes to several aspects of PD pathogenesis:
Alpha-synuclein toxicity: Alpha-synuclein aggregation affects ribosomal function and translation. Studies have shown that alpha-synuclein can directly interact with ribosomes and impair translation, potentially involving RPL10A [@linguin2018].
Mitochondrial dysfunction: PD is associated with mitochondrial dysfunction, which impacts cellular energy status and translation. RPL10A expression is modulated by mitochondrial stress, and this may contribute to the characteristic translational deficits in dopaminergic neurons [@gigure2019].
Lewy body pathology: Ribosomal proteins including RPL10A are found in Lewy bodies, suggesting they may be involved in the aggregation process or represent cellular stress response [@wakabayashi2020].
Ribosomal dysfunction is a key feature of ALS:
Translation defects: Motor neurons in ALS show impaired translation efficiency. RPL10A is differentially expressed in ALS spinal cord, suggesting a role in the disease process [@lo2021].
RNA metabolism: ALS is associated with defects in RNA metabolism. RPL10A's role in translation makes it relevant to this pathway, as many ALS-associated proteins regulate RNA processing.
Stress granules: Stress granules contain ribosomal proteins and translation factors. RPL10A is found in stress granules, which are dysregulated in ALS [@mateju2020].
Translation dysregulation: Huntington's disease is associated with broad translational deficits. Ribosomal profiling studies show reduced translation efficiency, with RPL10A potentially contributing to this deficit [@koch2021].
Mutant huntingtin effects: Mutant huntingtin protein affects ribosome function and assembly. RPL10A expression is altered in HD models, contributing to the characteristic translational impairment [@cervera2019].
Frontotemporal dementia (FTD) represents a group of disorders characterized by progressive neuronal loss in the frontal and temporal lobes. Ribosomal dysfunction has emerged as a significant contributor to FTD pathogenesis:
TDP-43 pathology: The majority of FTD cases involve TDP-43 proteinopathy. TDP-43 regulates RNA processing and translation, and its aggregation disrupts ribosomal function. Studies show that TDP-43 aggregates co-localize with ribosomal proteins in affected neurons, potentially including RPL10A [@neumann2020].
GRN mutations: Progranulin (GRN) mutations cause familial FTD. Progranulin is involved in lysosomal function and autophagy, which intersect with ribosomal quality control pathways. RPL10A dysfunction may contribute to the translational deficits observed in GRN-related FTD [@baker2021].
Stress granule dynamics: FTD is associated with altered stress granule biology. Stress granules contain ribosomal components and translation factors. RPL10A's presence in stress granules suggests a role in FTD pathogenesis through dysregulated stress response [@wolozin2019].
Progressive supranuclear palsy (PSP) is a tauopathy characterized by neurofibrillary tangles composed of hyperphosphorylated tau. Ribosomal dysfunction contributes to PSP pathogenesis:
Tau-ribosome interactions: Hyperphosphorylated tau directly interacts with ribosomes and translation machinery. RPL10A, as a core ribosomal protein, may be affected by these interactions, contributing to the characteristic translational deficits in PSP [@dickson2020].
Brainstem vulnerability: PSP affects brainstem nuclei including the substantia nigra. The selective vulnerability of specific neuronal populations may relate to their translational demands and RPL10A function.
Ribosomal dysfunction is a key feature of ALS:
Translation defects: Motor neurons in ALS show impaired translation efficiency. RPL10A is differentially expressed in ALS spinal cord, suggesting a role in the disease process [@lo2021].
RNA metabolism: ALS is associated with defects in RNA metabolism. RPL10A's role in translation makes it relevant to this pathway, as many ALS-associated proteins regulate RNA processing.
Stress granules: Stress granules contain ribosomal proteins and translation factors. RPL10A is found in stress granules, which are dysregulated in ALS [@mateju2020].
Corticobasal degeneration (CBD) is another tauopathy with overlapping features with PSP and AD. Ribosomal dysfunction contributes to CBD pathogenesis:
Cellular stress: CBD neurons exhibit severe cellular stress, including oxidative stress and ER stress. RPL10A's role in stress response integration makes it relevant to CBD pathophysiology.
Synaptic dysfunction: CBD affects cortical and basal ganglia circuits. Synaptic dysfunction is a key feature, and RPL10A's role in synaptic translation suggests involvement in CBD pathogenesis.
RPL10A interacts with multiple proteins that are relevant to neurodegeneration:
RPL10A expression is regulated through epigenetic mechanisms that may be relevant to neurodegeneration:
The RPL10A promoter contains CpG islands that may be differentially methylated in neurodegenerative diseases. Studies suggest that ribosomal protein gene promoters can be hypermethylated in AD, leading to altered expression [@sztuk2019].
Histone marks such as H3K9ac and H3K27ac are associated with active transcription of ribosomal protein genes. Dysregulation of these marks may contribute to RPL10A expression changes in disease.
RPL10A expression changes may serve as diagnostic biomarkers:
RPL10A expression levels correlate with disease progression:
RPL10A can serve as a biomarker for therapeutic efficacy:
RPL10A dysfunction leads to impaired ribosome assembly, reducing the capacity for protein synthesis. In neurons, where local translation is crucial for function, this has particularly severe consequences. Defects in 60S assembly affect:
RPL10A contributes to translational accuracy. Mutations or dysregulation of RPL10A can lead to:
These defects lead to the production of aberrant proteins that accumulate and trigger cellular stress pathways [@brandman2022].
The ribosome-associated quality control (RQC) pathway handles stalled ribosomes. RPL10A interfaces with RQC components including Ltn1 (RQC1), Rqc2, and ANP32. Defects in this pathway lead to:
RPL10A is involved in integrating cellular stress responses:
Integrated Stress Response (ISR): The ISR senses various stresses and modulates translation. RPL10A dysfunction can trigger or amplify ISR activation.
Oxidative stress: Oxidative stress affects ribosomal function. RPL10A oxidation leads to impaired translation and is observed in neurodegenerative disease models [@farrell2018].
ER stress: The unfolded protein response (UPR) affects ribosomal function. RPL10A plays a role in the cross-talk between ER stress and translation regulation.
Genome-wide association studies (GWAS) have identified variants near RPL10A that may influence AD risk. While not directly in the coding region, these associations suggest regulatory variants affecting RPL10A expression may modify disease risk [@jansen2019].
Rare variants in ribosomal protein genes have been implicated in PD. While direct pathogenic variants in RPL10A are not well-documented, the broader category of translation machinery genes shows enrichment for PD risk variants [@nalls2019].
Rare variants in ribosomal protein genes, including RPL10A, have been identified in ALS patients. These variants may affect ribosomal function and contribute to motor neuron vulnerability [@nicolas2018].
RPL10A knockout mice are embryonic lethal, demonstrating the essential nature of this protein. Conditional knockouts in specific tissues have revealed:
Zebrafish provide a tractable model for studying RPL10A function. Morpholino knockdown studies show:
Cell culture models have been used to study RPL10A:
While directly targeting RPL10A is challenging, several therapeutic strategies are being explored:
Translation modulators: Compounds that modulate translation rates may benefit from RPL10A's role in this process.
Ribosome enhancers: Drugs that improve ribosome assembly and function could address RPL10A-related deficits.
ISR inhibitors: Targeting the integrated stress response downstream of ribosomal dysfunction.
Several existing drugs affect ribosomal function and may be repurposed:
RPL10A expression can be measured in:
Changes in RPL10A levels may serve as biomarkers for:
Functional assays measuring:
These biomarkers could be used to monitor therapeutic efficacy.
RPL10A interacts with several key pathways relevant to neurodegeneration:
Related genes and proteins: